Evidence mapPaperPMID 39867495Full record

ReviewFrontiers in microbiology2024

Hyperlipidaemia treatment and gut microbiology.

Liu Zhe, Yu ChunLi

Abstract readReview
In one paragraph

Review in Frontiers in microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Liu ZheShaanxi Provincial Nuclear Industry 215 Hospital, Xianyang, Shaanxi, China.
Yu ChunLiShaanxi Provincial Nuclear Industry 215 Hospital, Xianyang, Shaanxi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Numerous studies have shown that hyperlipidaemia is closely related to the gut microbiota, and the study of microbiota in the treatment of hyperlipidaemia is undoubtedly a new target for the treatment and prevention of hyperlipidaemia. The efficacy of regulating the gut microecology and changing the structure of gut flora has been demonstrated by both western and traditional medication, biological therapy, and dietary exercise, so it is particularly important to study the relationship between gut microbiota and the treatment of hyperlipidaemia. In this review, we summarize the mechanism and relationship between the pathogenesis of hyperlipidaemia and gut microbiota, and the mechanism of hyperlipidaemia treatment by influencing the gut microbiota in various treatment modalities, which provides diversified therapeutic ideas and scientific basis for clinical treatment. It also triggers us to think about the relationship between gut microbiota and other diseases, and to explore the influence of gut microbiota is a goal that we still need to explore.

Indexed as

gut floragut microbiotahyperlipidaemiamechanismstreatment

Identifiers

PMID39867495
PMCPMC11758981

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.